Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD

Saved in:
Bibliographic Details
Main Authors: Mia Jensen, Steffen F. Nielsen, Steffen Thiel, Søren W.K. Hansen, Yaseelan Palarasah, Per Svenningsen, Jesper N. Bech, Frank H. Mose, Boye L. Jensen
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Kidney International Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924020357
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850127436589563904
author Mia Jensen
Steffen F. Nielsen
Steffen Thiel
Søren W.K. Hansen
Yaseelan Palarasah
Per Svenningsen
Jesper N. Bech
Frank H. Mose
Boye L. Jensen
author_facet Mia Jensen
Steffen F. Nielsen
Steffen Thiel
Søren W.K. Hansen
Yaseelan Palarasah
Per Svenningsen
Jesper N. Bech
Frank H. Mose
Boye L. Jensen
author_sort Mia Jensen
collection DOAJ
format Article
id doaj-art-12273d144af445409f22e2beb3265c30
institution OA Journals
issn 2468-0249
language English
publishDate 2025-02-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj-art-12273d144af445409f22e2beb3265c302025-08-20T02:33:40ZengElsevierKidney International Reports2468-02492025-02-0110259159510.1016/j.ekir.2024.11.014Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKDMia Jensen0Steffen F. Nielsen1Steffen Thiel2Søren W.K. Hansen3Yaseelan Palarasah4Per Svenningsen5Jesper N. Bech6Frank H. Mose7Boye L. Jensen8Unit of Cardiovascular and Renal Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark; Correspondence: Mia Jensen, Department for Molecular Medicine, Unit for Cardiovascular and Renal Research, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark.University Clinic in Nephrology and Hypertension, Gødstrup Hospital, Herning, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, DenmarkDepartment of Biomedicine, Aarhus University, Aarhus, DenmarkUnit of Cancer and Inflammation Research, Department of Molecular Medicine, University of Southern Denmark, Odense, DenmarkUnit of Cancer and Inflammation Research, Department of Molecular Medicine, University of Southern Denmark, Odense, DenmarkUnit of Cardiovascular and Renal Research, Department of Molecular Medicine, University of Southern Denmark, Odense, DenmarkUniversity Clinic in Nephrology and Hypertension, Gødstrup Hospital, Herning, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, DenmarkUniversity Clinic in Nephrology and Hypertension, Gødstrup Hospital, Herning, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, DenmarkUnit of Cardiovascular and Renal Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmarkhttp://www.sciencedirect.com/science/article/pii/S2468024924020357kidney injurylectin cascadetype 2 diabetes mellitus
spellingShingle Mia Jensen
Steffen F. Nielsen
Steffen Thiel
Søren W.K. Hansen
Yaseelan Palarasah
Per Svenningsen
Jesper N. Bech
Frank H. Mose
Boye L. Jensen
Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD
Kidney International Reports
kidney injury
lectin cascade
type 2 diabetes mellitus
title Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD
title_full Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD
title_fullStr Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD
title_full_unstemmed Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD
title_short Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD
title_sort pilot study of sodium glucose cotransporter 2 inhibitor empagliflozin shows reduced intrarenal complement activation in patients with diabetes and ckd
topic kidney injury
lectin cascade
type 2 diabetes mellitus
url http://www.sciencedirect.com/science/article/pii/S2468024924020357
work_keys_str_mv AT miajensen pilotstudyofsodiumglucosecotransporter2inhibitorempagliflozinshowsreducedintrarenalcomplementactivationinpatientswithdiabetesandckd
AT steffenfnielsen pilotstudyofsodiumglucosecotransporter2inhibitorempagliflozinshowsreducedintrarenalcomplementactivationinpatientswithdiabetesandckd
AT steffenthiel pilotstudyofsodiumglucosecotransporter2inhibitorempagliflozinshowsreducedintrarenalcomplementactivationinpatientswithdiabetesandckd
AT sørenwkhansen pilotstudyofsodiumglucosecotransporter2inhibitorempagliflozinshowsreducedintrarenalcomplementactivationinpatientswithdiabetesandckd
AT yaseelanpalarasah pilotstudyofsodiumglucosecotransporter2inhibitorempagliflozinshowsreducedintrarenalcomplementactivationinpatientswithdiabetesandckd
AT persvenningsen pilotstudyofsodiumglucosecotransporter2inhibitorempagliflozinshowsreducedintrarenalcomplementactivationinpatientswithdiabetesandckd
AT jespernbech pilotstudyofsodiumglucosecotransporter2inhibitorempagliflozinshowsreducedintrarenalcomplementactivationinpatientswithdiabetesandckd
AT frankhmose pilotstudyofsodiumglucosecotransporter2inhibitorempagliflozinshowsreducedintrarenalcomplementactivationinpatientswithdiabetesandckd
AT boyeljensen pilotstudyofsodiumglucosecotransporter2inhibitorempagliflozinshowsreducedintrarenalcomplementactivationinpatientswithdiabetesandckd